Skip to main content
Clinical Trials/ITMCTR2000003002
ITMCTR2000003002
Recruiting
Phase 1

A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy

Huangshi Hospital of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
severe novel coronavirus pneumonia (COVID-19)
Sponsor
Huangshi Hospital of Traditional Chinese Medicine
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Huangshi Hospital of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Hospitalized patients with novel coronavirus pneumonia confirmed by pathogenic detection
  • 2\. Meet any one of the criteria for severe type:
  • 1\) Respiratory distress: RP \>\= 30/min;
  • 2\) At rest, the oxygen saturation \<\= 93%;
  • 3\) Arterial partial pressure of oxygen (PaO2\)/Fraction of inspiration (FiO2\)(Oxygenation Index, P/F) \<\= 300mmHg.
  • 3\. Aged 18 to 75 years;
  • 4\. Signed informed consent.

Exclusion Criteria

  • 1\. Pregancy or lactating women;
  • 2\. People with allergies or allergies to components of Truncated Torsion formula;
  • 3\. Patients with serious basic diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage), hematological disease, HIV, etc.;
  • 4\. Patients with obstructive pneumonia caused by lung tumor, pulmonary fibrosis, alveolar proteinosis and allergic alveolitis;
  • 5\. Patients with long\-term use of hormone, immunosuppressant and other drugs;
  • 6\. Severe mental illness or inability to cooperate with investigators.

Outcomes

Primary Outcomes

Not specified

Similar Trials